243 related articles for article (PubMed ID: 18376265)
1. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
Dean JB; Hayashi SS; Albert CM; King AA; Karzon R; Hayashi RJ
J Pediatr Hematol Oncol; 2008 Feb; 30(2):130-4. PubMed ID: 18376265
[TBL] [Abstract][Full Text] [Related]
2. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
3. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
5. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
6. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens.
Kolinsky DC; Hayashi SS; Karzon R; Mao J; Hayashi RJ
J Pediatr Hematol Oncol; 2010 Mar; 32(2):119-23. PubMed ID: 20098336
[TBL] [Abstract][Full Text] [Related]
7. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
8. Platinum-induced hearing loss after treatment for childhood cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
[TBL] [Abstract][Full Text] [Related]
9. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
Knight KR; Kraemer DF; Neuwelt EA
J Clin Oncol; 2005 Dec; 23(34):8588-96. PubMed ID: 16314621
[TBL] [Abstract][Full Text] [Related]
10. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.
Parsons SK; Neault MW; Lehmann LE; Brennan LL; Eickhoff CE; Kretschmar CS; Diller LR
Bone Marrow Transplant; 1998 Oct; 22(7):669-74. PubMed ID: 9818694
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
12. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.
Orgel E; Jain S; Ji L; Pollick L; Si S; Finlay J; Freyer DR
Pediatr Blood Cancer; 2012 Jun; 58(6):953-8. PubMed ID: 21796767
[TBL] [Abstract][Full Text] [Related]
13. The incidence of hearing impairment after successful treatment of neuroblastoma.
Simon T; Hero B; Dupuis W; Selle B; Berthold F
Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
[TBL] [Abstract][Full Text] [Related]
14. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
Kushner BH; Budnick A; Kramer K; Modak S; Cheung NK
Cancer; 2006 Jul; 107(2):417-22. PubMed ID: 16779793
[TBL] [Abstract][Full Text] [Related]
15. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
[TBL] [Abstract][Full Text] [Related]
16. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
Waissbluth S; Del Valle Á; Chuang A; Becker A
Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
[TBL] [Abstract][Full Text] [Related]
17. Assessment of hearing in very young children receiving carboplatin for retinoblastoma.
Smits C; Swen SJ; Theo Goverts S; Moll AC; Imhof SM; Schouten-van Meeteren AY
Eur J Cancer; 2006 Mar; 42(4):492-500. PubMed ID: 16376542
[TBL] [Abstract][Full Text] [Related]
18. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.
Jehanne M; Lumbroso-Le Rouic L; Savignoni A; Aerts I; Mercier G; Bours D; Desjardins L; Doz F
Pediatr Blood Cancer; 2009 May; 52(5):637-43. PubMed ID: 19148943
[TBL] [Abstract][Full Text] [Related]
19. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.
Lambert MP; Shields C; Meadows AT
Pediatr Blood Cancer; 2008 Feb; 50(2):223-6. PubMed ID: 17278120
[TBL] [Abstract][Full Text] [Related]
20. Hearing impairment after platinum-based chemotherapy in childhood.
Einar-Jon E; Trausti O; Asgeir H; Christian M; Thomas W; Måns M; Jon K; Hannes P
Pediatr Blood Cancer; 2011 Apr; 56(4):631-7. PubMed ID: 21298751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
